In a 2‑month‑old infant with viral hepatitis and severe neutropenia (absolute neutrophil count 179 cells/µL) after four days of ampicillin, cefotaxime, and acyclovir, what is the appropriate management?

Management of Severe Neutropenia in a 2-Month-Old Infant with Viral Hepatitis

Immediately discontinue cefotaxime, as it is the most likely cause of the severe neutropenia (ANC 179 cells/µL) after four days of therapy, and switch to an alternative non-cephalosporin antibiotic while continuing supportive care and monitoring. 1

Primary Action: Identify and Remove the Offending Agent

The severe neutropenia (ANC 179 cells/µL) in this 2-month-old infant is most likely drug-induced, specifically from cefotaxime. The FDA label explicitly warns that "leukopenia, neutropenia, granulocytopenia and, more rarely, bone marrow failure, pancytopenia, or agranulocytosis may develop during treatment with cefotaxime" and recommends that "treatment discontinuation should be considered in case of abnormal results" 1. While the label mentions monitoring for courses longer than 10 days, severe neutropenia can occur earlier, particularly in vulnerable populations like young infants.

Acyclovir is a secondary but less likely culprit. There is documented evidence of acyclovir-induced neutropenia in infants, though it is rare. One case report describes neutropenia in a newborn receiving 30 mg/kg/day that resolved when the dose was reduced to 10 mg/kg/day 2. However, given the timing (4 days into therapy) and the known hematologic toxicity profile, cefotaxime is the primary suspect.

Ampicillin-induced neutropenia is possible but less common. Reversible neutropenia has been reported with high-dose ampicillin (150-400 mg/kg) in pediatric patients, typically occurring after 3-12 days of therapy 3. However, this is less frequently reported than cephalosporin-associated neutropenia.

Immediate Management Algorithm

Step 1: Discontinue Cefotaxime Immediately

• Stop cefotaxime now given the severe neutropenia (ANC <500 cells/µL) 1
• This is a critical threshold requiring immediate action

Step 2: Antibiotic Substitution Strategy

• Switch to a non-β-lactam antibiotic if bacterial infection remains a concern
• Consider aminoglycosides (gentamicin) as an alternative to cefotaxime for gram-negative coverage
• Continue ampicillin if tolerated, as it has a lower association with neutropenia than cefotaxime, though monitor closely 3
• If ampicillin must also be discontinued, consider vancomycin for gram-positive coverage

Important caveat: While cross-reactivity between β-lactams for neutropenia is theoretically possible, case reports suggest that switching from one β-lactam to another (e.g., ceftriaxone to ampicillin) can be successful without recurrent neutropenia 4. However, in this critically neutropenic infant, the safest approach is to avoid all cephalosporins.

Step 3: Acyclovir Management

• Consider dose reduction of acyclovir from standard dosing to 10 mg/kg/day if neutropenia persists after stopping cefotaxime 2
• Do not discontinue acyclovir abruptly if treating confirmed herpes simplex encephalitis or severe HSV infection, as mortality benefits are substantial 5
• Monitor closely for neutrophil recovery over 4-7 days

Step 4: Supportive Care and Monitoring

• Daily complete blood counts until neutrophil recovery begins
• Neutropenia from drug-induced causes typically resolves within 4-14 days after discontinuation 3, 4
• Consider G-CSF (granulocyte colony-stimulating factor) if neutropenia persists beyond 7 days or if clinical infection worsens 6, 7
• Maintain strict infection control precautions given severe neutropenia

Step 5: Infection Surveillance

• Monitor for fever, new signs of bacterial or fungal infection
• Blood cultures if fever develops
• Lower threshold for empiric antifungal therapy given ANC <500 cells/µL 8

Special Considerations for This Infant

The viral hepatitis itself is unlikely to be the primary cause of neutropenia. While acute hepatitis B can rarely cause bone marrow suppression and agranulocytosis 9, this typically occurs in the context of severe hepatitis with marked transaminase elevation and is more common in adults. In a 2-month-old, drug-induced neutropenia is far more likely given the temporal relationship with antibiotic initiation.

Age-specific vulnerability: Infants, particularly those under 3 months, may have baseline lower neutrophil counts and are more susceptible to drug-induced cytopenias 6, 10. The baseline ANC before starting antibiotics would be helpful but is likely unavailable.

Expected Timeline for Recovery

• Neutrophil count should begin rising within 4-11 days after discontinuing the offending agent 3
• Complete recovery typically occurs within 1-3 weeks 4
• If neutropenia persists beyond 2-3 weeks, consider bone marrow evaluation to rule out congenital neutropenia or other primary bone marrow disorders 11, 7

Critical Pitfalls to Avoid

1. Do not continue cefotaxime while "monitoring" the neutropenia—this risks progression to agranulocytosis
2. Do not assume the viral hepatitis is the cause without first addressing drug-induced etiologies
3. Do not discontinue acyclovir precipitously if treating confirmed HSV infection—the mortality benefit outweighs the neutropenia risk; instead, reduce the dose
4. Do not delay G-CSF if neutropenia persists beyond 7-10 days or if severe infection develops

The neutropenia in this case is almost certainly iatrogenic and reversible with appropriate antibiotic modification.